Azabenzthiazole inhibitors of leukotriene A4 hydrolase
摘要:
Previously, benzthiazole containing LTA4H inhibitors were discovered that were potent (1-3), but were associated with the potential for a hERG liability. Utilizing medicinal chemistry first principles (e. g., introducing rigidity, lowering cLogD) a new benzthiazole series was designed, congeners of 1-3, which led to compounds 7a, 7c, 12a-d which exhibited LTA4H IC50 = 3-6 nM and hERG Dofetilide Binding IC50 = 8.9-> >10 mu M. (C) 2012 Elsevier Ltd. All rights reserved.
[EN] NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES<br/>[FR] AMIDES DE DIAZABICYCLOALCANES SÉLECTIVES D'UN SOUS-TYPE DE RÉCEPTEUR D'ACÉTYLCHOLINE NICOTINIQUE
申请人:TARGACEPT INC
公开号:WO2009111550A1
公开(公告)日:2009-09-11
The present invention relates to compounds of the following formula (I) that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).
[EN] BENZODIOXANES FOR INHIBITING LEUKOTRIENE PRODUCTION<br/>[FR] BENZODIOXANNES POUR INHIBER LA PRODUCTION DE LEUCOTRIÈNES
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2013134226A1
公开(公告)日:2013-09-12
The present invention relates to compounds of formula (I) wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY
申请人:BYLOCK Lars Anders
公开号:US20130236468A1
公开(公告)日:2013-09-12
The present invention relates to a combination comprising compounds of formula (I):
wherein R
1
to R
3
, A, X and n are as defined herein, and an additional active agent. The present invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations to treat various diseases and disorders.
[EN] COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE<br/>[FR] COMPOSÉS POSSÉDANT DEUX GROUPEMENTS HÉTÉROARYLE BICYCLIQUES CONDENSÉS EN TANT QUE MODULATEURS DE LA LEUCOTRIÈNE A4 HYDROLASE
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2010132599A1
公开(公告)日:2010-11-18
Compounds with two fused bicyclic heteroaryl moieties of formula I and their pharmaceutical compositions, and methods of using them as leukotriene A4 hydrolase (LTA4H) modulators and for the treatment of diseases, disorders and conditions mediated by LTA4H.
Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase
申请人:Bacani Genesis M.
公开号:US20090258854A1
公开(公告)日:2009-10-15
Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity.